June 15, 2026 – Lesaffre, the global leader in yeast (France), and Unisons Biotechnology Co., Ltd. (China), a benchmark enterprise in probiotic smart manufacturing, have officially signed an exclusive strategic partnership on yeast strains for women’s health, and jointly launched a women’s health probiotic solution.
This innovative collaboration adopts a synergistic combination of “yeast-based probiotics + bacterial probiotics” to provide a superior and differentiated probiotic solution for the women’s health market.
Joining forces to deliver better solutions for women’s health
Quatreflora®, under Lesaffre’s Nutra’s division, is an internationally recognized patented yeast probiotic for women’s health. It holds a deposit number at the French National Collection of Microorganism Cultures (CNCM), multiple international authorized patents, and several peer-reviewed SCI journal clinical studies. Published clinical research has confirmed its efficacy in maintaining a healthy vaginal microbiota and inhibiting bacterial and fungal vaginal infections.
Unisons has independently developed proprietary patented probiotic strains for intimate women’s health, focusing on rapid lactic acid production, restoring acidic environment, and forming a protective barrier. The mechanisms of these two types of probiotics complement each other: yeast probiotics do not directly produce lactic acid, while bacterial probiotics excel at maintaining an acidic environment. Their synergy provides a “dual safeguard” for women’s intimate health.
Of particular note, yeast probiotics are naturally insensitive to common antibiotics and can be taken concurrently with antibiotics, unlike conventional bacterial probiotics that are easily killed by antibiotics. This means that for patients undergoing gynecological antibiotic therapy, this solution can be used simultaneously during antibiotic treatment, offering more continuous and reassuring adjunct support.
Why did a global yeast leader choose Unisons?
As a leading player in the global yeast industry, Lesaffre chose Unisons as its exclusive strategic partner not only because Unisons operates an Asia-leading, pharmaceutical-grade probiotic manufacturing facility, but also due to Unisons’ strong R&D innovation capabilities and the scientific synergy between the two teams.
Unisons has built a professional R&D center spanning over 3,700 square meters, with a research team led by doctorate holders and supported by master’s-level researchers. The company possesses a complete independent R&D system covering strain screening, functional evaluation, fermentation technology, freeze-drying protection, formulation development, and full-chain quality control. After in-depth discussions, both R&D teams discovered that combining Lesaffre’s yeast strains with Unisons’ bacterial strains achieves a mechanistic “1+1>2” effect. This synergy is not a simple stack of strains but a deep integration from action targets and metabolic pathways to application scenarios.
Unisons’ pharmaceutical-grade quality standards, “zero contamination” capability, and “Level 1 viability rate” production strength provide reliable technical support for the launch of Quatreflora® in the Chinese market.
Unisons is not just a “factory,” but a partner with independent scientific research capabilities and innovative vision. The true foundation of this exclusive partnership lies in the deep alignment in scientific philosophy, R&D approach, and quality pursuit—a dual match of “R&D + smart manufacturing.”
Conclusion
The collaboration between Lesaffre and Unisons goes far beyond the product level—it represents a paradigm of deep integration between an international brand and localized Chinese manufacturing. When a “170-year yeast giant” meets “Asia’s leading probiotic manufacturing standards,” what they are co-creating is not merely an agreement, but a highly promising new category with great growth potential.
